Valuation : Virbac

Market Cap 2.7B 3.13B 2.54B 2.32B 4.35B 297B 4.38B 30.05B 11.69B 151B 11.76B 11.5B 501B P/E 2026 *
15.8x
P/E 2027 * 14.3x
Enterprise Value 2.83B 3.28B 2.66B 2.42B 4.56B 311B 4.58B 31.46B 12.24B 158B 12.31B 12.04B 525B EV / Sales 2026 *
1.82x
EV / Sales 2027 * 1.69x
Free-Float
49.03%
Yield 2026 *
0.53%
Yield 2027 * 0.63%
1 day+0.47%
1 week-1.08%
Current month+0.16%
1 month-5.18%
3 months-8.56%
6 months-10.35%
Current year-8.03%
1 week 316
Extreme 316
327
1 month 316
Extreme 316
342.5
Current year 310.5
Extreme 310.5
381
1 year 297
Extreme 297
381
3 years 243
Extreme 243
392
5 years 220.5
Extreme 220.5
440.5
10 years 102.48
Extreme 102.479
440.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-1.08% - - 3.14B
+0.06%-0.32%-49.61%-59.98% 31.86B
+0.98%-4.05%+34.87%+94.31% 11.95B
+0.46%+3.70%-17.96%+7.03% 3.96B
0.00%-1.98%-3.30%+19.00% 3.14B
+1.19%+2.74%+50.06%+35.71% 2.05B
-0.28%-0.99%+10.69%+5.80% 1.94B
+1.54%+6.03%+3.84%+162.54% 1.53B
+1.33%+1.10%-21.81%-7.35% 1.17B
+0.29%+1.78%-9.99%-40.85% 1.04B
Average +0.61%+0.93%-0.36%+24.02% 6.51B
Weighted average by Cap. +0.33%-0.17%-19.65%-7.06%

Financials

2026 *2027 *
Net sales 1.55B 1.8B 1.46B 1.33B 2.5B 171B 2.51B 17.25B 6.71B 86.8B 6.75B 6.6B 288B 1.65B 1.91B 1.55B 1.41B 2.65B 181B 2.67B 18.32B 7.13B 92.19B 7.17B 7.01B 306B
Net income 171M 198M 161M 147M 276M 18.83B 277M 1.9B 741M 9.58B 745M 729M 31.75B 190M 220M 178M 162M 305M 20.85B 307M 2.11B 820M 10.61B 825M 807M 35.18B
Net Debt 127M 147M 119M 109M 204M 13.95B 205M 1.41B 549M 7.09B 552M 540M 23.52B 75.16M 87.13M 70.7M 64.41M 121M 8.27B 122M 836M 325M 4.21B 327M 320M 13.95B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change
01/09/26 320.50 +0.16%
31/08/26 €320.00 -0.78%
28/08/26 €322.50 -0.31%
27/08/26 €323.50 -1.07%
26/08/26 €327.00 +0.93%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
322.50EUR
Average target price
411.88EUR
Spread / Average Target
+27.71%

Quarterly revenue - Rate of surprise